Ling Jong, Senior Program Director, Medicinal Chemistry, Medicinal & Synthetic Chemistry

Toggle Menu

Ling Jong

Senior Program Director, Medicinal Chemistry, Medicinal & Synthetic Chemistry

Ling Jong, Ph.D., focuses on multiple drug discovery programs targeting cancer and infectious and neurodegenerative diseases. Jong regularly interacts with cross-functional teams performing work in fields ranging from drug design, in vitro cell biology, in vivo efficacy studies, and Investigational New Drug (IND)-enabling studies.

Jong has designed a number of first-in-class drugs and rapidly advanced them into clinical development during her 20 years of work in drug discovery and development at SRI. She was featured on the front page story in the Silicon Valley San Jose Business Journal for her anticancer drug discovery and development. Her works have been published in many peer-reviewed Journals such as Science and Nature. Jong holds more than 10 patents related to the treatment of cancer, infectious diseases, and Alzheimer’s disease.

Jong has received many awards for her work, including the Cornelius L. Hopper Award from the California Breast Cancer Research Program (CDMRP), Outstanding Funded Research from CDMRP/Prostate Cancer Research Program, and an Outstanding Achievement Award from SRI. Jong received a B.S. in chemistry from the National Chung-Hsing University in Taiwan and a Ph.D. in organic chemistry from Florida State University, Tallahassee.

Ling Jong